July 11, 2025
Operating Assets

Revenue Surge Amid Rising Expenses

Total Revenue: $150 million for the year ended December 31, 2024, up from $58.7 million in 2023. Revenue from Collaborative and Other Agreements: $118.9 million. MARGENZA Net Sales: $16.4 million. Contract Manufacturing Revenue: $13.1 million. Research and Development Expenses: $177.2 million, up from $166.6 million in 2023. Selling, General, and Administrative Expenses: $71 million, up

Read More
Intangible Assets

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has secured

Read More